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ABSTRACT 17 
 18 
In the present work, 79 structurally unrelated analytes were taken into account and their 19 
chromatographic retention coefficients, measured by Immobilized Artificial Membrane Liquid 20 
Chromatography (IAM-LC), and by Micellar Liquid Chromatography (MLC) employing sodium 21 
dodecyl sulfate (SDS) as surfactant, were determined. Such indexes, along with topological and 22 
physico-chemical parameters calculated in silico, were subsequently used for the development of 23 
Blood-Brain Barrier passage-predictive statistical models using partial least square (PLS) regression.. 24 
Highly significant relationships were observed either using IAM (r
2
 (n-1) = 0.78) or MLC (r
2 
(n-1) = 25 
0.83) derived indexes along with in silico descriptors. This hybrid approach proved fast and effective in 26 
the development of highly predictive BBB passage oriented models and, therefore, it can be of interest 27 
for pharmaceutical industries as a high-throughput BBB penetration oriented screening method. 28 
Finally, it shed new light into the molecular mechanism involved in the BBB uptake of therapeutics.  29 
 30 
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1.0 INTRODUCTION 33 
 34 
Pharmaceutical drug development is still a highly inefficient process: over one third of the failures 35 
in drug candidate development is estimated to occur due to unsatisfactory pharmacokinetic 36 
properties
1
, mainly regarding absorption, metabolism and toxicity and the attrition rates for Central 37 
Nervous System (CNS) active drugs are even higher
2
. In fact, before reaching the blood circulation, 38 
a drug diffuses through the biological barriers separating the circulating blood from the interstitial 39 
fluid that surrounds the tissues. For orally administered drugs, this barrier is the intestinal 40 
epithelium whereas the passage of drugs designed to act at the CNS level is further regulated by the 41 
Blood-Brain Barrier (BBB). The BBB is one of the most complex and extensively studied 42 
biological barriers, and its function is to preserve mammalian brain integrity against possible 43 
injurious substances. It is made of endothelial cells, narrowly adherent one to the other to form tight 44 
junctions, restricting the passage of solutes
3,4
.  Indeed, drug transport is strongly limited by this 45 
peculiar biological structure to pure passive transcellular diffusion. In fact, the paracellular route, 46 
i.e. the passage of actives through the gaps between each endothelial cell, is completely hindered. 47 
Apart from active transport mechanisms, whose occurrence is difficult to predict on a solely 48 
chemical structure basis, drugs can therefore cross the BBB only by the passive transcellular route.  49 
Plenty of in vivo, ex vivo, and in vitro methods are available for measuring BBB partitioning of 50 
analytes. Historically, one of the most used and reputed method is the determination of log BB 51 
values
5
. Log BB is defined as:  52 
 53 
log BB = log 
Blood
Brain
C
C
 54 
 55 
in which CBrain is the concentration that the analyte realizes in the brain tissues, and CBlood is the 56 
concentration that it realizes in the blood. However, this method involves the use of animal models, 57 
usually rodents, and does not provide any mechanistic information about the nature of the passage; 58 
furthermore, the method is time-consuming and potential source of ethical issues.  59 
Methods based on the employment of cultured cell lines can also be effective; however, astrocytes 60 
cell cultures are often difficult to grow and recreating an in vitro environment similar to the in vivo 61 
BBB can be challenging even for the most experienced scientists. Caco-2 model based methods 62 
may also be an alternative; however, apart from the structural dissimilarities with the other cell 63 
cultures
6
, they are difficult to standardize, complicating comparisons of data determined in different 64 
laboratories.   65 
In silico methods, generally based on the calculation of physico-chemical parameters, yield various 66 
advantages. They are much faster to perform, allowing the screening of large libraries of 67 
compounds (even solutes not yet synthesized); in addition, they can assist in the elucidation of the 68 
molecular mechanisms involved in membrane permeation. However, they also suffer from several 69 
limitations including the aspect that they are unable to take into account all phenomena actually 70 
occurring in vivo
7
 .  71 
In vitro methods based on the use of biomimetic stationary phases coupled with high performance 72 
liquid chromatography (HPLC) have been used to surrogate BBB permeation data
8,9
. The main 73 
advantages are that they are much more reproducible and easier to perform and, albeit conceptually 74 
simple, they can be incidentally able to provide an in-depth understanding of the mechanisms 75 
involved in membrane barrier passage. Such biomimetic stationary phases include, for instance, 76 
Immobilized Artificial Membranes (IAM). IAM stationary phases are based on analogues of 77 
phosphatidylcholine, which is the major component of biological membranes, and chromatographic 78 
retention coefficients of the analytes on such stationary phases are assumed as direct measures of 79 
their phospholipophilicity
10
, i.e. their affinity for phospholipids. Such measures have been proven to 80 
be able to mirror various phenomena underlying membrane barrier passage
8,11–13
. In addition, other 81 
chromatographic indexes, whose drug BBB-penetration predictivity has been demonstrated
14–16
, 82 
include those achieved by Micellar Liquid Chromatography (MLC) technique. This technique is 83 
based on the addition of surfactants to an aqueous mobile phase at concentrations higher than their 84 
critical micelle concentrations (CMC)
17
 resulting in the formation of micelles acting as a partition 85 
phase. Both IAM and MLC chromatographic indexes, mainly if combined with in silico calculated 86 
descriptors, have demonstrated effectiveness in the prediction of BBB drug penetration
16
. However, 87 
the methods proposed are still too time-consuming to meet the demands of pharmaceutical 88 
companies and their suitability should be confirmed on larger set of analytes.  89 
The aim of the present work has been the development of drug BBB penetration oriented statistical 90 
models based on analytical indexes, achieved on biomimetic conditions by medium/high-91 
throughput methods, along with in silico calculated descriptors. To the best of our knowledge, this 92 
is the study based on the highest number of compounds among those employing IAM and MLC 93 
data to predict drug pharmacokinetic properties. 94 
Therefore, particular attention is set on: 95 
i) the setup of medium/high-throughput methods for the achievement of both IAM and MLC 96 
indexes;  97 
ii) the validation of such parameters by developing statistical models for the prediction of BBB 98 
penetration (log BB) by using the chromatographic indexes along with in silico calculated 99 
descriptors; 100 
iii) the elucidation of the molecular mechanism involved in BBB passive diffusion of drugs; 101 
iv) the possibility of taking into account, by molecular docking studies, the occurrence of active 102 
efflux mechanisms. 103 
In the present work, 79 structurally unrelated analytes have been taken into account and their 104 
chromatographic retention coefficients, measured by high-throughput IAM-LC and MLC methods, 105 
the latter employing sodium dodecyl sulfate (SDS) as surfactant, were determined. Such indexes 106 
have subsequently been used for the development of BBB-passage predictive statistical models 107 
using partial least squares (PLS) automatic regression along with physico-chemical parameters, 108 
calculated in silico. Such hybrid approach was aimed at combining the speediness in the 109 
achievement of computational chemistry derived topological and physico-chemical parameters with 110 
the improved predictivity of the in vitro methods.  111 
 112 
2.0 RESULTS AND DISCUSSION  113 
The IAM-LC and MLC chromatographic retention coefficients, as well as the pKa, log BB values, 114 
UV wavelengths of the experimental determinations and suppliers, are presented in Table 1. In 115 
MLC, the highest retained compound (triprolidine) eluted within 33.0 minutes, whereas in IAM-LC 116 
the maximum run time was 37.0 minutes (fluphenazine). However, by performing either the MLC 117 
or the IAM-LC analytical methods, 85% of the compounds of the dataset eluted within 15.0 minutes 118 
and a preliminary estimate, as an order of magnitude, of the retention times expected can be easily 119 
performed based on the calculation of log D
7.4
 values of each compound present in the dataset. Two 120 
chromatographic runs for each technique are reported in Figure 1 (MLC) and Figure 2 (IAM-LC). 121 
The log BB values span a very large range (from -2.00 to +1.51) as the analytes to be included in 122 
the dataset were selected to include both CNS inactive (e.g. norfloxacin, nitrofurantoin) and CNS 123 
active (e.g. fluphenazine, desipramine) drugs. The P-gp affinities, expressed in kcal·mol
-1
, of the 124 
drugs considered are listed in Table 2A and Table 2B. They were incorporated in each of the 125 
following steps to model even the BBB passage of analytes undergoing P-gp effux mechanisms.  126 
  127 
 128 
Figure 1.  MLC chromatograms achieved for the analytes A) Imipramine (50 μg mL-1 in methanol) 129 
and B) Ethylbenzene (50 μg mL-1 in methanol) employing a mobile phase consisting of an aqueous 130 
solution of 0.05 mol·L
−1
 sodium dodecyl sulfate. The detailed experimental conditions are reported 131 
in paragraph 4.0. 132 
 133 
 134 
A 135 
 136 
 137 
B 138 
 139 
 140 
  141 
Figure 2.  IAM chromatograms achieved for the analytes A) Paroxetine (50 μg mL-1 in methanol) 142 
and B) Diclofenac (50 μg mL-1 in methanol). The mobile phase was a solution 70/30 v/v 143 
Dulbecco’s phosphate-buffered saline (DPBS) / methanol. The detailed experimental conditions are 144 
reported in paragraph 4.0. 145 
A 146 
 147 
 148 
B 149 
 150 
Table 1. pKa values, log kw 
SDS
, log k30%MeOH
IAM
 indexes, log BB values, experimental UV 151 
wavelengths and suppliers for the analytes taken into account. 152 
 153 
Analyte pKa 
log kw 
SDS
 
log 
k30%MeOH
IAM log BB 
UV wavelength 
(nm) 
Supplier 
 
 
 
2-
(Methylamino)pyridine 
- 1.611 -0.164 -0.30
18
 254 Sigma-
Aldrich 
  
2,2,2-trifluoroethyl 
vinyl ether 
- 0.929 -0.142 0.13
18
 210 Sigma-
Aldrich 
  
2,6-diisopropylphenol - 1.688 1.097 0.91
19
 210 TCI 
Europe 
  
Acetaminophen 9.69 -0.092 -0.204 -1.00
19
 254 Acros 
Organics 
  
Acetylsalicylic acid 3.50 -0.301 -0.274 -1.30
19
 230 Acros 
Organics 
  
Aminopyrine 5.03 1.486 -0.206 0.00
19
 254 Sigma-
Aldrich 
  
Amitriptyline 9.17 2.230 1.606 1.30
19
 254 TCI 
Europe 
  
Amobarbital 7.48/11.15* 1.208 0.059 0.04
19
 210 Sigma-
Aldrich 
  
Antipyrine 1.44 1.059 -0.277 -0.10
19
 240 Acros 
Organics 
  
Atenolol 9.19 1.156 -0.162 -1.00
19
 270 Acros 
Organics 
  
Benzene - 1.202 0.036 0.37
20
 210 TCI 
Europe 
  
Betahistine 7.84 0.125 -0.193 -0.30
21
 254 Acros 
Organics 
  
Caffeine 0.60 0.910 -0.284 -0.06
19
 210 Acros 
Organics 
  
Carbamazepine - 1.191 0.210 0.00
19
 210 Acros 
Organics 
  
Celecoxib 9.38 1.461 1.613 -1.00
21
 254 Acros 
Organics 
  
Chlorambucil 4.60 0.787 0.308 -1.70
19
 254 TCI 
Europe 
  
Chlorpromazine 9.50 2.169 2.038 1.36
21
 254 TCI 
Europe 
  
Cimetidine 7.01 1.003 -0.177 -1.42
19
 210 TCI 
Europe 
  
Citalopram 9.22 1.832 1.005 0.48
21
 210 TCI 
Europe 
  
Clonidine 8.08 1.436 0.171 0.11
19
 270 TCI 
Europe 
  
Clozapine 7.90 1.784 1.529 0.60
21
 254 TCI 
Europe 
  
Cotinine - 1.424 -0.260 -0.32
19
 260 TCI 
Europe 
  
Cyclobenzaprine 8.47 2.092 1.607 1.08
21
 230 TCI 
Europe 
  
Desipramine 10.28 2.144 1.536 1.20
19
 254 Sigma-
Aldrich 
  
Diclofenac 3.99 0.602 0.024 -1.70
21
 254 Acros 
Organics 
  
Diphenhydramine 8.86 2.077 0.858 1.20
21
 210 Acros 
Organics 
  
Domperidone 9.68 1.937 1.562 -0.78
19
 270 TCI 
Europe 
  
Donepezil 8.54* 1.968 0.858 0.89
22
 210 Acros 
Organics 
  
Eserine 8.17 1.656 0.030 0.08
19
 240 TCI 
Europe 
  
Ethosuximide 9.27 0.545 -0.228 0.04
21
 210 Acros 
Organics 
  
Ethylbenzene - 1.588 0.600 0.26
20
 210 Acros 
Organics 
  
Fluphenazine 7.84/2.08* 2.207 2.066 1.51
19
 254 Sigma-
Aldrich 
  
Haloperidol 8.29 2.366 1.483 1.34
22
 254 TCI 
Europe 
  
Halothane - 1.215 0.152 0.35
20
 210 Sigma-
Aldrich 
  
Hexobarbital 8.20 1.284 -0.008 0.10
19
 254 Sigma-
Aldrich 
  
Hydroxyzine 7.52/1.58* 2.038 1.337 0.90
21
 210 Sigma-
Aldrich 
  
Ibuprofen 4.24 0.626 0.090 -0.18
19
 270 Acros 
Organics 
  
Imipramine 9.52 2.190 1.452 1.30
19
 240 Acros 
Organics 
  
Indomethacin 4.13 0.647 -0.257 -1.26
19
 210 TCI 
Europe 
  
Ketorolac 3.84 -0.097 -0.500 -2.00
21
 300 TCI 
Europe 
  
Lamotrigine 5.36 1.316 -0.006 0.48
23
 220 Acros 
Organics 
  
Levofloxacin 6.20/5.45* 1.388 -0.099 -0.70
21
 290 TCI 
Europe 
  
Metanol - 0.000 -0.447 0.02
23
 210 Sigma-
Aldrich 
  
Metoclopramide 9.71 1.610 0.346 0.08
21
 210 TCI 
Europe 
  
Metoprolol 9.56 1.771 0.198 1.15
22
 220 TCI 
Europe 
  
Mianserin 6.92 2.152 1.456 0.99
19
 280 TCI 
Europe 
  
Naproxen 4.14 0.153 -0.090 -1.70
21
 254 Acros 
Organics 
  
Nicotine 8.11 1.969 -0.139 0.40
20
 210 Acros 
Organics 
  
Nitrofurantoin 7.05 -0.074 -0.447 -2.00
21
 254 Acros 
Organics 
  
Norfloxacin 8.68/5.77* 1.332 -0.062 -1.00
21
 280 Acros 
Organics 
  
Nortriptyline 10.13 2.169 1.639 1.04
21
 254 TCI 
Europe 
  
Olanzapine 7.80 1.825 0.843 0.80
21
 254 TCI 
Europe 
  
Omeprazole 9.29/4.77* 1.591 -0.229 -0.82
19
 300 TCI 
Europe 
  
Oxazepam - 1.420 0.707 0.61
19
 230 Sigma-
Aldrich 
  
Paroxetine 9.77 2.104 1.796 0.48
21
 210 TCI 
Europe 
  
Pentobarbital 8.18 1.243 0.103 0.12
19
 210 Sigma-
Aldrich 
  
Phenylbutazone 4.34 0.996 0.273 -0.52
19
 240 Acros 
Organics 
  
Phenytoin 8.28 1.311 0.382 -0.04
19
 210 Acros 
Organics 
  
Pindolol 9.54 0.811 0.312 0.30
21
 210 Sigma-
Aldrich 
  
Primidone - 0.710 -0.152 -0.07
21
 210 TCI 
Europe 
  
Promazine 9.36 2.030 1.643 1.23
20
 254 Sigma-
Aldrich 
  
Promethazine 9.00 2.040 1.613 1.30
24
 254 TCI 
Europe 
  
Propranolol 9.16 2.028 0.992 0.85
21
 290 Acros 
Organics 
  
Quinidine 8.56 2.245 0.982 0.33
22
 230 Acros 
Organics 
  
Ranitidine 8.33 1.233 -0.239 -1.23
19
 230 TCI 
Europe 
  
Rifampicin 1.70 1.900 0.990 -1.52
21
 230 TCI 
Europe 
  
Ropinirole 10.17 1.685 0.326 0.25
19
 254 Sigma-
Aldrich 
  
Salicylic acid 2.82 -0.280 -0.302 -1.10
19
 300 Acros 
Organics 
  
Theobromine - 0.347 -0.284 -0.28
19
 270 Acros 
Organics 
  
Theophylline - 0.447 -0.218 -0.29
19
 270 Acros 
Organics 
  
Toluene - 1.459 0.330 0.37
20
 210 Acros 
Organics 
  
Tramadol 9.41 1.692 0.256 0.70
21
 210 Sigma-
Aldrich 
  
Trazodone 7.30 2.223 0.780 0.30
21
 210 Sigma-
Aldrich 
  
Triprolidine 8.64 2.493 0.789 0.78
21
 230 Sigma-
Aldrich 
  
Valproic acid 4.54 0.001 -0.279 -0.84
19
 210 Acros 
Organics 
  
Venlafaxine 9.67 1.900 0.429 0.48
25
 230 Acros 
Organics 
  
Verapamil 8.68 2.271 1.169 -0.52
19
 210 Acros 
Organics 
  
Zidovudine 9.40 0.271 -0.264 -1.00
20
 270 Acros 
Organics 
  
Zolmitriptan 9.55 0.974 -0.159 -1.40
21
 220 TCI 
Europe 
  
 154 
* calculated by Marvin Sketch 15.1 software 155 
 156 
  157 
Table 2A. Minimum and most populated values, expressed in kcal mol
-1
, of the cluster affinities of 158 
the analytes for the first four (from 1 to 4) discrete binding sites located on the P-gp. 159 
 160 
 161 
Analyte 
 
P-gp 
1 Min 
P-gp 
1 MP  
P-gp 
2 Min 
P-gp 
2 MP  
P-gp 
3 Min 
P-gp 
3 MP  
P-gp 
4 Min 
P-gp 
4 MP  
2-(Methylamino)pyridine -3.03 -3.03 -3.61 -3.61 -3.62 -3.62 -3.63 -3.63 
2,2,2-trifluoroethyl vinyl ether -1.72 -1.72 -2.09 -2.09 -1.85 -1.85 -1.98 -1.94 
2,6-diisopropylphenol -4.42 -4.42 -5.36 -5.36 -5.55 -5.55 -5.36 -5.36 
Acetaminophen -3.30 -3.30 -4.72 -4.72 -4.13 -4.08 -4.85 -4.85 
Acetylsalicylic acid -3.57 -3.57 -4.47 -4.36 -4.48 -4.48 -4.22 -3.95 
Aminopyrine -4.43 -4.30 -5.66 -5.66 -5.63 -5.63 -5.70 -5.70 
Amitriptyline -6.09 -5.02 -7.29 -7.15 -6.39 -6.39 -7.22 -7.22 
Amobarbital -4.14 -4.06 -5.30 -5.00 -4.83 -4.83 -5.05 -5.05 
Antipyrine -4.33 -4.33 -5.61 -5.61 -5.31 -5.31 -5.61 -5.44 
Atenolol -3.81 -3.34 -5.74 -3.99 -3.82 -3.40 -4.83 -4.70 
Benzene -2.72 -2.72 -3.31 -3.31 -3.31 -3.31 -3.31 -3.31 
Betahistine -3.06 -3.06 -3.68 -3.68 -3.32 -3.14 -3.70 -3.70 
Caffeine -3.80 -3.80 -4.60 -4.60 -4.23 -4.23 -4.33 -4.33 
Carbamazepine -5.84 -5.82 -7.09 -7.09 -6.12 -6.12 -7.07 -7.07 
Celecoxib -4.30 -4.30 -7.01 -6.98 -4.73 -4.12 -7.18 -7.18 
Chlorambucil -3.77 -3.77 -5.13 -4.81 -5.19 -5.19 -5.16 -5.16 
Chlorpromazine -5.38 -4.84 -7.24 -7.24 -6.57 -6.57 -7.26 -7.26 
Cimetidine -3.27 -2.95 -4.74 -4.60 -4.10 -4.02 -4.70 -4.64 
Citalopram -4.75 -4.45 -6.41 -6.14 -4.93 -4.93 -7.16 -6.86 
Clonidine -4.34 -4.34 -5.41 -5.41 -5.44 -5.44 -5.40 -5.40 
Clozapine -5.10 -5.05 -7.01 -7.01 -5.36 -5.36 -7.00 -6.98 
Cotinine -3.93 -3.87 -5.14 -4.79 -4.92 -4.92 -4.82 -4.82 
Cyclobenzaprine -6.32 -5.14 -7.18 -7.04 -6.94 -6.94 -7.14 -7.14 
Desipramine -5.75 -5.43 -6.80 -6.62 -6.26 -6.08 -6.53 -6.53 
Diclofenac -5.23 -4.96 -6.34 -6.13 -6.49 -6.19 -6.14 -6.05 
Diphenhydramine -4.35 -3.91 -5.63 -5.63 -5.14 -5.14 -5.61 -5.61 
Domperidone -5.23 -4.82 -7.12 -6.98 -6.39 -6.39 -7.18 -7.18 
Donepezil -6.05 -6.05 -7.70 -7.46 -6.69 -6.67 -7.72 -7.65 
Eserine -4.88 -4.88 -6.01 -5.87 -5.45 -5.45 -5.91 -5.91 
Ethosuximide -3.62 -3.62 -4.22 -4.22 -4.47 -4.39 -4.42 -4.42 
Ethylbenzene -3.34 -3.34 -4.22 -4.22 -4.07 -4.07 -4.07 -4.07 
Fluphenazine -4.81 -3.58 -6.75 -6.75 -4.30 -4.12 -6.60 -5.82 
Haloperidol -4.35 -4.17 -6.25 -6.25 -5.60 -5.60 -7.23 -6.20 
Halothane -2.12 -2.12 -2.76 -2.75 -2.74 -2.72 -2.66 -2.64 
Hexobarbital -4.85 -4.79 -6.02 -6.02 -5.13 -4.97 -6.03 -6.03 
Hydroxyzine -4.24 -3.67 -6.41 -5.43 -4.05 -3.66 -6.19 -5.84 
Ibuprofen -4.37 -4.37 -5.52 -5.43 -5.88 -5.88 -5.43 -5.34 
Imipramine -5.34 -5.34 -6.68 -6.68 -5.76 -4.64 -6.68 -6.13 
Indomethacin -5.67 -5.53 -7.02 -7.02 -7.28 -7.28 -7.37 -7.37 
Ketorolac -5.22 -5.22 -6.61 -6.61 -6.55 -6.41 -6.62 -6.62 
Lamotrigine -4.49 -3.92 -5.84 -5.84 -4.88 -4.56 -5.36 -5.36 
Levofloxacin -4.45 -4.45 -5.80 -5.54 -5.80 -5.23 -6.07 -5.85 
Metanol -1.40 -1.33 -1.43 -1.43 -1.33 -1.33 -1.40 -1.40 
Metoclopramide -3.47 -3.47 -5.19 -3.92 -3.71 -3.07 -4.52 -4.13 
Metoprolol -3.58 -3.35 -4.63 -4.06 -3.54 -2.87 -4.39 -4.18 
Mianserin -5.23 -5.23 -7.06 -7.06 -6.05 -5.98 -7.11 -7.11 
Naproxen -4.82 -4.82 -5.99 -5.99 -6.03 -5.91 -6.03 -6.03 
Nicotine -4.02 -4.02 -4.70 -4.69 -4.50 -4.50 -4.70 -4.70 
Nitrofurantoin -4.10 -4.10 -5.33 -5.33 -5.18 -5.18 -5.32 -5.32 
Norfloxacin -3.83 -3.83 -5.59 -5.59 -5.51 -5.51 -5.75 -5.63 
Nortriptyline -6.35 -6.35 -7.07 -6.86 -6.44 -6.44 -7.00 -7.00 
Olanzapine -4.60 -4.60 -6.71 -6.62 -5.47 -5.29 -6.68 -6.68 
Omeprazole -5.26 -5.20 -6.96 -6.76 -6.65 -6.41 -7.16 -6.92 
Oxazepam -5.29 -5.29 -6.90 -6.90 -6.16 -6.16 -6.89 -6.89 
Paroxetine -4.94 -4.94 -6.95 -6.84 -6.42 -5.67 -6.83 -6.29 
Pentobarbital -3.88 -3.88 -4.76 -4.76 -4.41 -4.41 -4.91 -4.91 
Phenylbutazone -5.53 -5.53 -7.27 -7.27 -6.02 -5.12 -7.45 -6.69 
Phenytoin -5.00 -5.00 -6.56 -6.56 -5.39 -5.00 -6.55 -6.55 
Pindolol -4.17 -4.13 -5.43 -4.86 -4.56 -4.26 -5.47 -4.60 
Primidone -4.55 -4.55 -5.19 -5.19 -4.88 -4.71 -5.50 -5.50 
Promazine -5.58 -5.58 -6.79 -6.50 -6.32 -6.32 -6.50 -5.84 
Promethazine -4.99 -4.80 -6.78 -6.49 -6.60 -5.83 -6.51 -6.42 
Propranolol -4.60 -4.38 -6.33 -5.54 -4.79 -4.22 -6.10 -5.39 
Quinidine -5.72 -5.72 -7.43 -7.43 -5.26 -4.56 -7.77 -7.77 
Ranitidine -2.77 -2.65 -4.11 -3.91 -4.42 -2.88 -4.31 -3.48 
Rifampicin -7.10 -6.50 -4.48 -4.32 -6.80 -5.95 -7.22 -6.59 
Ropinirole -4.02 -4.01 -6.30 -5.55 -4.72 -3.94 -5.94 -5.52 
Salicylic acid -3.09 -3.09 -3.69 -3.69 -4.00 -4.00 -3.74 -3.71 
Theobromine -3.47 -3.47 -4.54 -4.54 -4.08 -4.08 -4.54 -4.54 
Theophylline -3.63 -3.63 -4.43 -4.43 -3.88 -3.87 -4.43 -4.43 
Toluene -3.08 -3.08 -3.81 -3.81 -3.77 -3.77 -3.74 -3.74 
Tramadol -4.89 -4.89 -5.94 -5.20 -5.15 -3.77 -5.71 -5.30 
Trazodone -5.37 -5.00 -7.30 -5.74 -5.79 -6.47 -7.09 -6.06 
Triprolidine -5.03 -4.92 -7.19 -7.11 -5.36 -5.36 -6.96 -6.88 
Valproic acid -2.78 -2.78 -3.56 -3.56 -3.81 -3.81 -3.43 -3.43 
Venlafaxine -4.81 -4.54 -6.07 -5.82 -4.54 -4.09 -6.47 -6.08 
Verapamil -3.93 -3.54 -6.56 -6.37 -5.28 -4.48 -6.58 -6.14 
Zidovudine -3.45 -3.21 -5.14 -5.14 -3.56 -3.27 -5.20 -5.20 
Zolmitriptan -4.48 -4.32 -6.32 -6.01 -5.56 -5.56 -6.38 -5.73 
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Table 2B. Minimum and most populated values, expressed as kcal mol
-1
, of the cluster affinities of 163 
the analytes for the second four (from 5 to 8) discrete binding sites located on the P-gp. 164 
   165 
Analyte 
 
P-gp 
5 Min 
P-gp 5 
MP  
P-gp 
6 Min 
P-gp 
6 MP  
P-gp 
7 Min 
P-gp 
7 MP  
P-gp 
8 Min 
P-gp 
8 MP  
2-(Methylamino)pyridine 
-3.03 -3.03 -3.40 -3.40 -3.53 -3.53 -3.22 -3.22 
2,2,2-trifluoroethyl vinyl ether -1.72 -1.64 -2.05 -2.05 -2.18 -2.18 -1.93 -1.93 
2,6-diisopropylphenol 
-4.42 -4.22 -5.17 -5.17 -5.56 -5.56 -4.67 -4.67 
Acetaminophen 
-3.81 -3.81 -4.20 -4.20 -4.10 -4.10 -3.37 -3.37 
Acetylsalicylic acid -3.86 -3.86 -3.91 -3.91 -4.42 -4.42 -3.68 -3.68 
Aminopyrine 
-5.20 -5.18 -5.36 -4.91 -5.60 -5.60 -4.47 -4.47 
Amitriptyline 
-6.00 -5.92 -6.85 -6.85 -7.49 -7.49 -5.63 -5.63 
Amobarbital -4.51 -4.51 -4.40 -4.05 -4.99 -4.99 -4.23 -4.23 
Antipyrine 
-4.78 -4.78 -4.77 -4.77 -5.58 -5.58 -4.31 -4.30 
Atenolol 
-4.03 -4.03 -4.82 -4.60 -4.86 -4.86 -3.37 -3.37 
Benzene -3.19 -3.19 -3.26 -3.26 -3.31 -3.31 -3.01 -3.01 
Betahistine 
-2.93 -2.93 -3.54 -3.54 -3.52 -3.52 -3.41 -3.41 
Caffeine 
-3.64 -3.64 -3.76 -3.76 -4.56 -4.56 -3.76 -3.76 
Carbamazepine -5.87 -5.87 -6.16 -6.16 -6.83 -6.83 -5.31 -5.31 
Celecoxib 
-5.93 -5.31 -5.82 -5.82 -7.97 -7.97 -5.59 -5.04 
Chlorambucil 
-4.30 -4.30 -4.57 -4.56 -5.63 -5.63 -3.93 -3.93 
Chlorpromazine -5.66 -5.00 -6.75 -6.57 -7.23 -7.01 -5.16 -5.16 
Cimetidine 
-3.72 -3.45 -4.58 -3.80 -4.76 -3.88 -3.41 -3.20 
Citalopram 
-5.63 -5.59 -5.85 -5.69 -6.44 -6.44 -4.93 -4.86 
Clonidine -4.06 -3.98 -4.47 -4.40 -5.34 -5.34 -4.31 -4.31 
Clozapine 
-5.44 -5.18 -6.64 -6.64 -7.05 -7.05 -4.98 -4.95 
Cotinine 
-4.52 -4.52 -4.48 -4.48 -4.86 -4.76 -4.29 -4.29 
Cyclobenzaprine -5.70 -5.68 -7.12 -6.86 -7.35 -7.23 -5.36 -5.28 
Desipramine 
-5.74 -5.74 -6.44 -6.44 -6.42 -5.73 -4.78 -4.78 
Diclofenac 
-5.23 -5.23 -5.96 -5.46 -6.32 -6.32 -4.65 -4.37 
Diphenhydramine -5.07 -5.07 -5.41 -4.78 -5.42 -5.42 -3.89 -3.54 
Domperidone 
-6.04 -5.71 -5.73 -5.73 -7.69 -7.69 -6.26 -6.13 
Donepezil 
-7.11 -6.10 -7.07 -7.07 -7.83 -7.77 -6.58 -6.58 
Eserine -5.52 -5.50 -5.57 -5.57 -5.92 -5.92 -4.57 -4.54 
Ethosuximide 
-3.62 -3.62 -4.16 -4.16 -4.34 -4.34 -3.76 -3.35 
Ethylbenzene 
-3.58 -3.58 -3.96 -3.96 -4.21 -4.21 -3.71 -3.71 
Fluphenazine -4.39 -4.39 -5.23 -3.06 -6.46 -5.16 -5.79 -5.79 
Haloperidol 
-5.68 -5.14 -5.35 -4.41 -7.32 -7.31 -5.48 -5.35 
Halothane 
-2.37 -2.37 -2.57 -2.55 -2.86 -2.86 -2.41 -2.35 
Hexobarbital -5.21 -4.99 -5.22 -5.22 -5.51 -5.51 -4.56 -4.50 
Hydroxyzine 
-5.26 -4.29 -5.29 -5.29 -6.18 -5.89 -4.57 -4.50 
Ibuprofen 
-4.84 -4.84 -4.91 -4.69 -5.41 -5.41 -4.55 -4.55 
Imipramine -5.83 -5.18 -6.69 -6.32 -6.67 -6.67 -4.97 -4.97 
Indomethacin 
-5.92 -5.92 -6.44 -6.44 -7.22 -6.91 -5.26 -5.26 
Ketorolac -5.73 -5.68 -5.71 -5.63 -6.36 -6.35 -5.01 -4.74 
Lamotrigine 
-4.13 -4.09 -4.77 -4.77 -5.30 -5.23 -4.32 -3.66 
Levofloxacin 
-5.40 -5.14 -3.46 -3.46 -6.37 -6.37 -4.71 -4.71 
Metanol -1.47 -1.47 -1.38 -1.38 -1.37 -1.37 -1.42 -1.42 
Metoclopramide 
-3.63 -3.36 -4.40 -4.02 -4.95 -4.95 -3.55 -2.80 
Metoprolol 
-3.49 -3.46 -4.25 -4.25 -4.60 -4.39 -3.57 -3.42 
Mianserin -5.89 -5.89 -6.21 -6.21 -7.07 -7.07 -5.63 -5.63 
Naproxen 
-5.26 -5.26 -5.48 -5.48 -5.80 -5.80 -4.72 -4.71 
Nicotine 
-3.77 -3.77 -4.42 -4.20 -4.67 -4.67 -4.24 -4.13 
Nitrofurantoin -4.37 -4.30 -4.62 -4.31 -5.24 -5.24 -3.90 -3.67 
Norfloxacin 
-4.46 -4.44 -3.73 -2.70 -5.85 -5.83 -4.99 -4.99 
Nortriptyline 
-5.98 -5.98 -7.20 -7.20 -7.09 -7.07 -5.30 -5.05 
Olanzapine -5.42 -5.42 -6.24 -6.24 -6.48 -6.48 -5.06 -5.06 
Omeprazole 
-5.24 -5.22 -6.47 -6.47 -7.26 -6.79 -5.28 -4.22 
Oxazepam 
-5.96 -5.94 -6.61 -6.61 -6.81 -6.70 -5.02 -5.02 
Paroxetine -5.71 -5.03 -6.14 -4.23 -7.49 -6.50 -4.97 -4.97 
Pentobarbital 
-4.29 -4.18 -4.35 -4.22 -4.84 -4.84 -3.75 -3.60 
Phenylbutazone 
-6.29 -6.19 -7.19 -7.19 -7.33 -6.78 -5.57 -5.44 
Phenytoin -5.80 -5.80 -5.42 -5.38 -6.25 -6.25 -4.67 -4.64 
Pindolol 
-3.61 -3.58 -5.72 -5.72 -5.29 -5.13 -4.03 -3.81 
Primidone 
-4.43 -4.31 -4.99 -4.99 -5.23 -5.23 -4.26 -4.08 
Promazine -5.47 -4.86 -6.22 -5.94 -6.47 -6.05 -4.71 -4.50 
Promethazine 
-5.55 -4.99 -6.07 -5.87 -6.62 -6.40 -4.72 -4.68 
Propranolol 
-4.42 -4.42 -5.99 -5.19 -5.67 -5.62 -4.30 -4.30 
Quinidine -5.68 -5.68 -6.74 -5.62 -7.92 -7.78 -5.32 -4.72 
Ranitidine 
-2.99 -2.99 -3.61 -3.34 -3.76 -2.86 -2.12 -1.63 
Rifampicin 
-5.13 -3.28 -6.66 -6.00 -7.44 -7.00 -3.14 -3.14 
Ropinirole -4.25 -4.17 -5.98 -5.98 -6.22 -6.22 -4.11 -3.39 
Salicylic acid 
-3.09 -3.09 -3.42 -3.42 -3.85 -3.85 -3.31 -3.31 
Theobromine 
-3.46 -3.46 -3.49 -3.49 -4.29 -4.29 -3.80 -3.80 
Theophylline -3.63 -3.63 -3.72 -3.72 -4.45 -4.45 -3.66 -3.66 
Toluene 
-3.42 -3.42 -3.79 -3.79 -3.93 -3.93 -3.39 -3.39 
Tramadol 
-4.46 -4.46 -5.36 -5.36 -5.62 -5.46 -4.26 -4.26 
Trazodone -6.06 -6.26 -6.86 -6.86 -7.40 -7.29 -6.06 -5.47 
Triprolidine 
-6.48 -6.48 -6.40 -5.53 -7.28 -7.28 -5.38 -5.26 
Valproic acid 
-3.03 -3.03 -3.10 -3.10 -3.76 -3.76 -2.90 -2.90 
Venlafaxine -4.64 -4.33 -5.60 -5.23 -6.48 -6.48 -4.40 -4.40 
Verapamil 
-5.16 -4.84 -4.74 -3.51 -6.80 -6.53 -4.32 -3.72 
Zidovudine 
-3.94 -3.93 -4.49 -4.49 -4.55 -4.55 -3.90 -3.19 
Zolmitriptan -4.78 -3.70 -6.13 -6.13 -6.15 -6.15 -4.42 -4.42 
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2.1 MLC INDEXES IN LOG BB PREDICTION  167 
MLC indexes were used to develop BBB passage potential predicting models along with either 168 
static or conformational properties. At first, all the analytes were assumed as having zero atomic 169 
charges, even the ones supporting one or more ionizable functions. The equations along with the 170 
statistical validation are reported in Table 3. In the equations thereby reported, r
2 
is the multiple 171 
regression coefficient, q
2 
is the r
2
 validated by Leave-One-Out (LOO) optimization, SE is the error 172 
standard deviation, F represents the Fischer regression statistical value, PC is the Amemiya 173 
predictive criterion and ExRow is the analyte excluded for maximizing the predictive strength of 174 
the statistical model. If not differently indicated, every regression was developed by employing four 175 
different independent variables (MLC indexes + three other physico-chemical descriptors). 176 
Surprisingly, even if over two thirds of the analytes support one or more ionizable functions, fairly 177 
good relationships, as the one expressed by equations (1) and (2), are obtained even not taking into 178 
account the presence of electric charges. This may be attributed to the fact that, although the 179 
molecular mechanisms involved in MLC are multiple and complex, the occurrence of 180 
analyte/micelles electrostatic interactions plays a pivotal role in the global retention and it appears 181 
reasonable to assume that such interactions are encoded in MLC indexes. It should be also 182 
highlighted that, in these specific cases, being VirtualLogP values calculated starting from the 183 
analytes assumed in their forms having zero atomic charges, such values can be reasonably assumed 184 
as estimates of their log P
N
 values. Subsequently, the analytes supporting extensively ionizable 185 
functions (i.e. carboxy groups, for acids primary, secondary and tertiary amines for bases) were 186 
assumed as completely charged, regardless of the relative abundance of the charged species at the 187 
physiological pH. Considering the ionizable analytes as entirely charged species slightly worsened 188 
the relationships (equations (3) and (4)). It should be pointed out that verapamil, the analyte 189 
excluded to maximize the predictive strength of the statistical model is a well-known P-gp 190 
substrate
26
. P-gp is an ATP-dependent efflux pump, with broad substrate specificity which pumps 191 
many foreign substances out of cells
27
. Although it is widely expressed in the intestinal epithelium, 192 
liver cells and proximal tubule of the kidney, P-gp is also localized in the capillary endothelial cells 193 
composing the BBB and is responsible, for some classes of actives, of multi-drug resistance. 194 
Eventually, a weighted average of the static properties at physiological pH (7.4), according to the 195 
pKa of each compound, was performed. For zwitterions, the static properties were calculated for 196 
each microspecies possibly present at pH 7.4 and their relative abundances, calculated by the 197 
software Marvin Sketch 15.1 for Mac OS X
28
, were also used to perform the weighted averages. 198 
The relative abundances of the microspecies present at pH 7.4 are reported in the Supporting 199 
Information section for the ampholytes levofloxacin (page S-2), norfloxacin (page S-4) and 200 
omeprazole (page S-6). This approach was adapted to mirror more closely what actually occurs in 201 
vivo. Performing the weighted average of the properties benefited noticeably the relationships as 202 
described by equations (5) and (6). It is also interesting to note how, according to the above 203 
reported relationships, the BBB penetration of drugs will be enhanced for highly retained 204 
compounds in MLC, how it is hindered by the occurrence of drug/membrane polar (Psa)/ 205 
electrostatic (Dipole) interactions, and how the transport through the barrier seems favored for 206 
bases (Charge). However, by taking into account the analytes assumed as static, the properties are 207 
derived considering them in their minimum energy conformations, i.e. after minimization. Indeed, 208 
several authors
29
 reported that such conformations are not always the ones actually involved in 209 
membrane barrier passage. Therefore, a conformational analysis in vacuum was carried out for each 210 
analyte included in the data set by using the Boltzmann Jump method that generates at random 1000 211 
possible conformations by exploring the conformational space of the rotatable dihedral angles. The 212 
conformational analysis was first performed on the analytes assumed as having zero atomic 213 
charges, then on the analytes assumed as completely charged and finally taking into account a 214 
weighted average of the properties at the experimental pH 7.4, according to the pKa of each analyte. 215 
In the following models the conformational properties were considered separately to look into the 216 
predictive strength of the models. As it is evident from Table 3, the use of conformational 217 
properties instead of the static ones slightly worsened the relationships. This aspect is quite 218 
interesting as the calculation of conformational properties can be rather time-consuming especially 219 
if the compound libraries to screen are wide and the computers employed are not sufficiently 220 
powerful. Conversely, the static properties are much faster to calculate. Performing the weighted 221 
average of the conformational properties yielded the most predictive models (equations (11) and 222 
(12)) and in those relationships, verapamil again behaved as an outlier, suggesting that such models 223 
would not be able to mirror the penetration of analytes undergoing some sort of active transport, in 224 
this case P-gp mediated efflux. It is interesting to point out how, among the ionized properties 225 
employed for the statistical method development (equations (9) and (10)), no one depends 226 
noticeably on ionization. Furthermore, the conformational analysis demonstrated how it is the PSA 227 
Max, i.e. the maximum value that the PSA assumes by exploring the conformational space in 228 
vacuum of each analyte, that best relates with log BB values as those values are incorporated in 229 
each model based on conformational properties (equations (7), (8), (9), (10), (11) and (12)).  230 
  231 
Table 3. Statistical validation of the models developed employing log kw
SDS  
values
 
of the dataset 232 
(n=79) along with three other physico-chemical descriptors. 233 
 234 
MOLECULAR 
DESCRIPTORS 
r2 q2 SE F PC r2 
(n-
1) 
SE 
(n-1) 
F (n-
1) 
PC (n-
1) 
EX-ROW EQUATIONS EQ 
No 
STATIC              
ZERO ATOMIC 
CHARGES 
PROPERTIES 
0.69 0.65 0.521 41.42 21.656 0.71 0.510 44.06 20.535 - 
 
 
 
 
 
 
 
2-
(Methylamino) 
pyridine 
log BB = -
0.2693 + 0.8191 
log kw
SDS - 
0.0162 Psa - 
0.0824 
VirtualLogP + 
0.1456 HbDon 
 
log BB = -
0.2166 + 0.8383 
log kw
SDS - 
0.0170 Psa - 
0.0994 
VirtualLogP + 
0.1570 HbDon 
1 
 
 
 
 
 
 
 
2  
IONIZED 
PROPERTIES 
0.68 0.63 0.530 39.28 22.452 0.70 0.517 42.20 21.104 - 
 
 
 
 
 
 
 
Verapamil  
log BB = -
0.3460 + 0.6671 
log kw
SDS - 
0.0104 Psa + 
0.1425 Charge - 
0.0138 
Impropers 
 
log BB = -
0.4024 + 0.7071 
log kw
SDS - 
0.0093 Psa + 
0.1297 Charge - 
0.0187 
Impropers 
3 
 
 
 
 
 
 
 
4 
WEIGHTED 
AVERAGE 
0.72 0.68 0.498 47.05 19.795 0.73 0.486 50.29 18.617 - 
 
 
 
 
 
 
Verapamil  
log BB = -
0.3145 + 0.6825 
log kw
SDS - 
0.0091 Psa - 
0.0202 Dipole + 
0.2042 Charge 
 
log BB = -
0.3145 + 0.6825 
log kw
SDS - 
0.0091 Psa - 
5 
 
 
 
 
 
 
6 
0.0202 Dipole + 
0.2042 Charge 
CONFORMATIONAL              
ZERO ATOMIC 
CHARGES 
PROPERTIES 
0.69 0.64 0.526 40.25 22.081 0.71 0.509 44.37 20.426 - 
 
 
 
 
 
 
 
Pindolol 
 
log BB = -
0.4857 + 0.8201 
log kw
SDS - 
0.0044 PSA 
Max - 0.0708 
MD Max - 
0.2671 MD sd 
 
log BB = -
0.4973 + 0.8307 
log kw
SDS - 
0.0048 PSA 
Max - 0.0583 
MD Max - 
0.3274 MD sd 
 
7 
 
 
 
 
 
 
 
8 
 
IONIZED 
PROPERTIES 
0.65 0.62 0.549 69.77 23.504 0.67 0.538 74.60 22.304 - 
 
 
 
 
 
Primidone  
log BB = -
0.5392 + 0.7898 
log kw
SDS - 
0.0093 PSA 
Max  
 
log BB = -
0.5338 + 0.8008 
log kw
SDS - 
0.0099 PSA 
Max  
9 
 
 
 
 
 
10 
WEIGHTED 
AVERAGE 
0.68 0.63 0.534 38.57 22.729 0.70 0.520 41.69 21.283 - 
 
 
 
 
 
 
 
 
 
Verapamil 
log BB = -
0.4329 + 0.7969 
log kw
SDS - 
0.0072 PSA 
Max - 0.0235 
MD Min - 
0.0485 MLP 
Average 
 
 
log BB = -
0.4911 + 0.8121 
log kw
SDS - 
0.0068 PSA 
Max - 0.0233 
MD Min - 
0.0334 MLP 
Average 
11 
 
 
 
 
 
 
 
 
 
12 
2.2 IAM INDEXES IN LOG BB PREDICTION  235 
The same approach was extended to the IAM indexes. The equations along with the statistical 236 
validation coefficient are reported in Table 4. Indeed, taking into account either the properties of the 237 
analytes assumed as having zero atomic charges (equations (13) and (14)) or those of the analytes 238 
assumed as completely charged (equations (15) and (16)) resulted in a BBB passage predictive 239 
strength inferior to that obtained by using MLC indexes. Such conclusions are supported by the 240 
lower correlation coefficients obtained. It is interesting to note how domperidone, the compound 241 
excluded in first best optimized model described by equation (14), is a well-known substrate of the 242 
P-gp
26
, and is pumped out of cells by such efflux system despite its high biomembrane passive 243 
diffusion. Analogously to what was observed in the analysis of MLC indexes, performing the 244 
weighted average of the static properties resulted the winning strategy also for this set of 245 
experimental measures. In fact, a 0.72 r
2
 (n-1), achieved on a set as large as 79 analytes, employing 246 
only four descriptors suggests that the model (equations (17) and (18)) is robust and reliable 247 
However, these relationships are roughly comparable to those obtained by using MLC indexes 248 
(equations (5) and (6)). This evidence is indeed rather surprising, since the IAM stationary phase 249 
consists of analogues of phosphatidylcholine, the most abundant phospholipid expressed in the 250 
capillary endothelium acting as a barrier between the blood and the cerebrospinal fluids (CSF), and 251 
thus they would represent an ideal biomimetic system. Conversely, this kind of SDS based MLC 252 
should have drawbacks arising from the different chemical structure of SDS in comparison with 253 
membrane phospholipids. But this evidence would suggest that they are incidentally able to mirror 254 
the drug/membrane interactions involved in vivo thanks to the peculiar amphiphilic features of the 255 
anionic micelles.  In fact, for some reasons, they seem to be able to model the passive BBB 256 
penetration of drugs fairly better than IAM indexes. Furthermore, the physico-chemical descriptors 257 
reported in equation (18) are the same as the ones in equation (6), supporting again the concept 258 
according to which the polar (Psa) /electrostatic (Dipole) interaction component plays a relevant 259 
role in hindering the BBB penetration of drugs. Again, bases seem to be favored in BBB entering 260 
and this is also consistent with the clinical experience. In fact, polar and extensively protonated at 261 
pH 7.4 basic compounds, such as amphetamine and methamphetamine, are known to have an 262 
appreciable CNS activity but it is much harder to recall similar cases for polar acids. The 263 
conformational analyses of the analytes neither assumed as having zero atomic charges, nor as 264 
ionized benefitted the relationships. Moreover, even performing the weighted average was not 265 
beneficial at all for the relationships (data not shown).  266 
  267 
Table 4. Statistical validation of the models developed employing log k30% MeOH 
IAM  
values
 
of the 268 
dataset (n=79) along with three other physico-chemical descriptors. 269 
 270 
MOLECULAR 
DESCRIPTORS 
r2 q2 SE F PC r2 
(n-
1) 
SE 
(n-1) 
F (n-
1) 
PC (n-
1) 
EX-ROW EQUATIONS EQ 
No 
STATIC              
ZERO ATOMIC 
CHARGES 
PROPERTIES 
0.64 0.59 0.561 33.08 25.156 0.67 0.540 36.88 23.025 - 
 
 
 
 
 
 
Domperidone 
log BB = +0.6691 + 
0.8369 log k30% 
MeOH
IAM - 0.0166 Psa - 
0.1473 VirtualLogP + 
0.1139 HbDon 
 
log BB = +0.6706 + 
0.9057 log k30% 
MeOH
IAM - 0.0161 Psa - 
0.1473 VirtualLogP + 
0.1173 HbDon 
13 
 
 
 
 
 
 
14  
IONIZED 
PROPERTIES 
0.64 0.58 0.561 33.07 25.155 0.67 0.540 37.29 22.976 - 
 
 
 
 
 
 
Lamotrigine  
log BB = -0.3460 + 
0.5276 log k30% 
MeOH
IAM + 0.0680 
HbAcc - 0.0164 Psa - 
0.3020 Charge 
 
log BB = 0.3429 + 
0.5324 log k30% 
MeOH
IAM + 0.1027 
HbAcc + 0.3288 
Charge - 0.0188 Psa 
15 
 
 
 
 
 
 
16 
WEIGHTED 
AVERAGE 
0.70 0.65 0.515 42.79 21.169 0.72 0.494 47.40 19.219 - 
 
 
 
 
 
 
Celecoxib  
log BB = +0.4388 + 
0.5458 log k30% 
MeOH
IAM - 0.0110 Psa - 
0.0190 Dipole + 
0.4653 Charge 
 
log BB = +0.3773 + 
0.6063 log k30% 
MeOH
IAM- 0.0097 Psa - 
0.0207 Dipole + 
0.4182 Charge 
17 
 
 
 
 
 
 
18 
  271 
2.3 IAM + MLC INDEXES IN LOG BB PREDICTION  272 
In the present study, MLC and IAM indexes were, in a first instance, considered separately. 273 
However, the evident differences in the elution order observed depict a rather different selectivity 274 
between both techniques. For this reason, the development of the BBB entering potential statistical 275 
models was also performed by considering both the chromatographic indexes at the same time, 276 
along with three other molecular descriptors (five independent variables in total), starting from the 277 
weighted average of the molecular properties. This strategy resulted in a markedly improved 278 
predictive strength (equations (19) and (20)) as reported in Table 5. These relationships may 279 
suggest that the molecular mechanism involved in IAM-LC and MLC are different but play both a 280 
relevant role in BBB diffusion of drugs.  281 
2.4 P-GP AFFINITIES IN LOG BB PREDICTION  282 
As already mentioned, each analyte present in the dataset was docked into each discrete binding site 283 
on the P-gp and the binding affinities were incorporated in the development of BBB passage 284 
predictive statistical models. Indeed, recent fuctional studies have identified seven sometimes 285 
overlapping binding sites accommodating substrates and inhibitors in the greasy, polyspecific 286 
binding cavity of P-gp. These binding sites were demonstrated able to allosterically communicate in 287 
a negative heterotropic manner. Moreover, an additional binding site was recognized on the exterior 288 
of P-gp bounded by residues from the transmembrane helices 9, 12 and the elbow helix 2. This site 289 
faces away from the transporter, lying close to the predicted membrane–water interface and 290 
intramembranous substrate-entry portal.  291 
On average , highly clustered results were achieved, meaning that the conformational search 292 
procedure was exhaustive enough to ensure a coverage of the accessible conformational space. An 293 
extensive cluster analysis (RMSD tolerance was set to 2.0 Å) was performed and the binding 294 
affinity now reported in Table 2A and Table 2B are the minimum and the most populated binding 295 
energies of the clusters. The errors of the estimates of free energies of binding were never higher 296 
than ± 1.8 kcal mol
-1
. However, from the relationships reported above, P-gp affinities do not seem 297 
to have an appreciable role in BBB passage. However, this is not entirely true because the statistical 298 
model development was carried out using only four independent variables, thus leading the 299 
software to select only the four most relevant descriptors, among which P-gp affinities were not 300 
included. Indeed, when five independent variables were set in the statistical method development, 301 
the P-gp binding affinities (Table 5A and 5B) were used by the software to build up the models. 302 
Equations (21) and (22), generated by IAM indexes and four static properties of the analytes, 303 
assumed as having zero atomic charges, is an example as can be seen in Table 5. The AutoDock 304 
GPF/DPF files for site 1 and 7, i.e. the ones actually involved in the statistical models (21) and (22), 305 
are now provided as supplementary materials.  306 
This is not surprising because among the considered analytes, the only ones known from the 307 
literature to be substrates of P-gp are cimetidine, domperidone, ranitidine, rifampicin, quinidine and 308 
verapamil
26
, and they represent less than 5% of the dataset. Indeed, the compounds considered were 309 
selected in the attempt to mirror as accurately and completely as possible the marketed drugs, in 310 
terms of diverse chemical nature, molecular volume, CNS activity and molecular lipophilicity. 311 
Since the active transport comprises only for a minority of drugs, whereby the drug uptake in 312 
mainly driven by passive transcellular diffusion, the limited predictivity of the P-gp molecular 313 
affinity may be dataset related. This approach suffers from some limitations, the most evident one 314 
being the aspect that the receptor flexibility is not taken into account. The main reason behind it is 315 
the large number of degrees of freedom that should be considered in this kind of calculations, thus 316 
requiring remarkable computational power. However, neglecting the receptor flexibility could lead 317 
to poor docking results in terms of binding pose prediction in real-world settings. Therefore, these 318 
results must be regarded as a preliminary attempt to gain new insights and model the active efflux 319 
of drugs pumped out of cells by P-gp, being neither exhaustive nor complete. Other experiments 320 
have to be performed and docking conditions further calibrated in order to validate the proposed 321 
model.    322 
  323 
Table 5. Statistical validation of the models developed employing either log kw
SDS
 or log k30% MeOH 324 
IAM
 values
 
of the dataset (n=79) along with four (equations (29-32)) or five (equations (25-28)) 325 
other physico-chemical descriptors. 326 
 327 
 328 
STATIC r2 q2 SE F PC r2 (n-
1) 
SE (n-
1) 
F (n-
1) 
PC (n-
1) 
EX-ROW EQUATIONS EQ 
No 
MLC + IAM 0.74 0.69 0.477 42.45 18.409 0.77 0.454 48.09 16.447 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
Domperidone 
 
log BB = -
0.0521 + 
0.5338 log 
kw
SDS + 
0.3799 log 
k30%MeOH
IAM - 
0.0093 PSA - 
0.0252 Dipole 
- 0.1057 
VirtualLog P   
 
log BB = -
0.0506 + 
0.5134 log 
kw
SDS + 
0.4466 log 
k30%MeOH
IAM - 
0.0086 PSA - 
0.0266 Dipole 
- 0.1120 
VirtualLogP  
19 
 
 
 
 
 
 
 
 
 
 
 
 
20 
 
P-GP AFFINITIES + 
IAM 
0.67 0.61 0.544 29.30 23.925 0.69 0.521 32.50 21.653 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Celecoxib 
log BB = 
0.8837 + 
0.9206 log k 
IAM - 0.0131 
Psa - 0.2781 
P-gp 1 Min  - 
0.1399 
VirtualLogP 
+ 0.2742 P-gp 
7 MP 
 
log BB = 
0.8118 + 
0.9239 log 
k30%MeOH
IAM - 
0.0135 Psa - 
0.1574 
VirtualLogP - 
0.2825 P-gp 1 
Min + 0.2575 
21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
P-gp 7 MP 
  
DRAGON 
DESCRIPTORS 
            
MLC 0.80 0.78 0.416 75.54 13.794 0.83 0.393 86.64 12.164 - 
 
 
 
 
 
 
 
 
 
 
Verapamil 
 
log BB = -
0.1663 + 
0.6102 log 
kw
SDS - 0.0085 
TPSA (NO) - 
0.8563 
nRCOOH - 
0.0079 
D/Dr05 
 
log BB = -
0.2220 + 
0.6483 log 
kw
SDS - 0.0078 
TPSA (Tot) - 
0.8677 
nRCOOH - 
0.0081 
D/Dr05 
 
23 
 
 
 
 
 
 
 
 
 
 
24 
 
IAM 0.76 0.73 0.457 59.13 16.711 0.78 0.440 65.45 15.242 - 
 
 
 
 
 
 
 
 
 
 
 
Verapamil  
log BB = 
+0.4564 + 
0.5250 log 
k30% MeOH
IAM- 
0.0091 TPSA 
(NO) -1.0354 
nRCOOH – 
0.0073 
D/Dr05  
 
log BB = 
+0.4450 + 
0.5490 log 
k30% MeOH
IAM- 
0.0086 TPSA 
(NO) – 
1.0457 
nRCOOH – 
0.0082 
D/Dr05   
25 
 
 
 
 
 
 
 
 
 
26 
 329 
 330 
  331 
2.5 E-DRAGON DESCRIPTORS IN MAXIMIZING THE PREDICTIVE STRENGTH OF THE 332 
MODELS 333 
In an attempt to further maximize the predictive strength of the models, IAM and MLC indexes 334 
were used in combination with E-Dragon descriptors
30
. The E-Dragon software calculates more 335 
than 1,600 descriptors, including not only the simplest atom type, functional group and fragment 336 
counts, but also several topological and geometrical descriptors. The results and statistical method 337 
validation are reported in Table 5.  Remarkably high correlation coefficients were achieved with 338 
either IAM (r
2
 = 0.78, equation (26)) or MLC (r
2
= 0.83, equation (24)). As suggested by the 339 
similarly high q
2
 values, those relationships are not affected by any over fitting. The plots of the 340 
experimental vs predicted log BB values (as predicted by equation (24)) are reported in Figure 3. 341 
Such relationship is based on MLC indexes, TPSA (Tot) i.e. the topological polar surface area using 342 
nitrogen, oxygen, sulphur, phosphorus polar contributions which differs from the TPSA (NO), 343 
included, for instance in equations (23), (25) and (26) that instead takes into account, in the 344 
topological polar surface area computation the nitrogen and oxygen contributions only. nRCOOH 345 
and D/Dr 05 are included in all the equations reported in Table 5. While the former is a functional 346 
group descriptor referring to the number of aliphatic carboxylic acids, the latter is a topological 347 
descriptor, named distance/detour ring index of order 5. It is based on operation over the 348 
distance/detour matrix D/∆, a square symmetric matrix that contains the ratios of the lengths of the 349 
shortest to the longest path between any pair of vertices. It is calculated by the following equation:  350 
 351 
Although the role that such a parameter could play in the BBB partition is unclear, being its 352 
interpretation quite difficult, it cannot be excluded that it might affect the molecular flexibility of 353 
the analytes. However, the models obtained starting from E-Dragon descriptors would again 354 
support the view according to which the BBB penetration of drugs would be enhanced for highly 355 
retained compounds either in IAM or MLC and hindered for compounds having greater PSA and 356 
supporting one or even more acidic functions. To further validate the proposed method, the datasets 357 
were divided randomly into 16 pairs of training and test sets. For each pair, the multiple linear 358 
regression was performed and the equations derived from the training sets were subsequently used 359 
to predict the log BB values of the test sets. Such value set was used to evaluate the regression 360 
coefficient (r
2
), the standard error (SE) of the estimates and the Fischer coefficients. The results of 361 
this additional validation are shown in Table 6.  362 
 363 
Table 6. Validation of the best model employing four descriptors for log BB prediction.  364 
 365 
Model Validation 
Trial 
Training set Test set 
r
2
 SE F r
2
 SE 
1 0.87 0.320 57.459 0.75 0.496 
2 0.85 0.412 46.645 0.71 0.445 
3 0.84 0.411 45.880 0.71 0.498 
4 0.84 0.390 45.696 0.74 0.488 
5 0.84 0.415 43.969 0.75 0.433 
6 0.84 0.394 43.432 0.75 0.450 
7 0.83 0.389 41.407 0.77 0.455 
8 0.81 0.427 35.093 0.76 0.445 
9 0.80 0.444 35.085 0.78 0.411 
10 0.80 0.438 34.173 0.77 0.430 
11 0.80 0.426 33.984 0.79 0.453 
12 0.80 0.482 33.303 0.79 0.372 
13 0.80 0.444 33.181 0.78 0.424 
14 0.79 0.444 32.284 0.79 0.413 
15 0.77 0.462 28.660 0.81 0.404 
16 0.75 0.476 25.656 0.82 0.393 
 366 
.  367 
 368 
  369 
Figure 3. Experimental vs Predicted log BB values plot for the best model obtained in the present 370 
study (Eq. (24)). 371 
 372 
 373 
 374 
 375 
 376 
  377 
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3.0 CONCLUSION  378 
 379 
Highly significant (r
2
 (n-1) up to 0.83) statistical methods for the BBB entering potential of drugs 380 
were achieved by applying the proposed method, which incidentally shed new light into BBB 381 
penetration of drugs.  In fact, the BBB passage was found related to the analyte charges, being 382 
hindered for compounds supporting one or more acidic functions, and enhanced for bases. 383 
Moreover, molecules with higher dipolar momentum and greater PSA seemed less prone to cross 384 
the BBB. The relatively high number of analytes taken into account support statistically the 385 
suitability of the method as early screening method to evaluate BBB passage, and consolidate the 386 
novelty of the present work. In the modeling of drugs’ BBB passage, both IAM and MLC indexes 387 
are found advantageously suitable; however, their combination with physico-chemical descriptors is 388 
highly beneficial for prediction. From a theoretical point of view, it should be considered that both 389 
IAM and MLC indexes relate to BBB passage data despite the different interactions they depict as 390 
confirmed by the lack of co-linearity between those two analytical indexes. Again, their 391 
simultaneous use in the statistic models, here performed for the first time, improved their prediction 392 
strength, thus suggesting that both play a relevant role in BBB passage although mirroring different 393 
phenomena. The P-gp efflux has also been investigated, but our results indicate that it would affect 394 
the overall BBB drug uptake only negligibly. However, this conclusion should be regarded 395 
cautiously due to the aspect that only a fewP-gp substrates were included in the set of analytes 396 
considered. Furthermore, the molecular docking simulations suffer from several limitations, the 397 
most important being the aspect that the receptor flexibility is not taken into account. This might 398 
have played a role in the moderate predictivity of the in silico calculated P-gp binding affinities.  399 
Finally, the proposed method is also suitable for pharmaceutical companies in the search for 400 
accurate BBB penetration oriented screening methods as the chromatographic conditions were 401 
carefully studied to obtain the indexes in a relatively short time such as to meet their demands. 402 
Chromatographic indexes (MLC and IAM) were always included in the best statistical models; this 403 
implies that the information encoded in such measures is original and cannot be satisfactorily 404 
surrogated by other in silico descriptors. The molecular modeling performed was simple, easy-to-405 
perform and can be configured to run automatically in case of batch analyses. Furthermore, as the 406 
method is rather cheap and relies on basic HPLC equipment, it offers potential for broad scale 407 
application 408 
4.0 EXPERIMENTAL SECTION   409 
 410 
4.1 CHEMICALS  411 
 412 
The solutes were obtained from Sigma-Aldrich (Machelen, Belgium), TCI-Europe (Zwijndrecht, 413 
Belgium) and Thermofisher Acros Organics (Geel, Belgium) as listed in Table 1 and their purity 414 
was equal to or higher than 98%.   415 
 416 
4.2 ANALYTICAL COLUMNS  417 
MLC and IAM experiments were performed on an Agilent Zorbax SB-C18 Rapid Resolution (3.5 418 
μm, 50 mm x 2.1 mm; Santa Clara, CA, USA) and Regis IAM Fast Mini Screening (10 μm, 10 mm 419 
× 3.0 mm; Morton Grove, IL, USA) columns, respectively.  420 
4.3 APPARATUS  421 
 422 
4.3.1 MLC-HPLC  423 
MLC chromatographic analysis was performed on an Alliance, Waters 2690 chromatograph 424 
(Milford, MA, USA) with a quaternary pump and an automatic injector. A Waters 2487 dual-425 
wavelength absorbance ultraviolet detector was used. The applied detection wavelengths for the 426 
various solutes were always in the range between 210 and 300 nm as listed in Table 1. Data 427 
acquisition and processing were performed using a PeakSimple Chromatography Data System 428 
(model 202) and PeakSimple software (SRI Instruments, Torrance, CA, USA). The temperature of 429 
the analysis was controlled by a Polaratherm series 9000 unit (Selerity Technologies, Salt Lake 430 
City, USA) and set at 37 °C. The flow rate was 1.0 mL min
-1 
and the injection volume was 20 L.  431 
4.3.2. IAM-HPLC  432 
IAM based chromatographic analysis was performed on an Agilent Capillary 1200 system (Santa 433 
Clara, CA, USA). The system included a capillary pump, a micro vacuum degasser and an 434 
automatic injector. An Agilent 1200 Series variable wavelength detector was used and set at the 435 
maximum absorbance wavelength of each analyte.  The IAM-HPLC experiments were carried out 436 
at room temperature (20 ± 2 °C), the flow rate was 300 L min-1 and the injection volume was 1 L.  437 
4.4 MOBILE PHASE AND SAMPLE PREPARATION  438 
MLC mobile phases were composed of aqueous solutions of 0.05 mol·L
−1
 sodium dodecyl sulfate 439 
(SDS) (Acros). Water (18.2 MΩ·cm-1) was purified and deionized in house via a Milli-Q plus 440 
instrument from Millipore (Bedford, New Hampshire, USA). pH was adjusted to pH 7.4 by 441 
phosphate buffer, prepared with 0.05 mol·L
-1
 disodium hydrogen phosphate (Sigma–Aldrich) and 442 
potassium dihydrogen phosphate (Sigma–Aldrich). To reproduce the osmotic pressure of biological 443 
fluids, NaCl (9.20 g·L
-1
) (Sigma–Aldrich) was added to the micellar mobile phase. IAM mobile 444 
phases consisted of a solution 70/30 v/v Dulbecco’s phosphate-buffered saline (DPBS) / methanol 445 
(HPLC-grade; Biosolve, Valkenswaard, The Netherlands). DPBS was composed of 2.7 mmol·L
−1
 446 
KCl, 1.5 mmol·L
−1
 potassium dihydrogen phosphate, 137.0 mmol·L
−1
 NaCl, and 8.1 mmol·L
−1
 447 
disodium hydrogen phosphate (Sigma–Aldrich). Such solution had a pH value of 7.40  0.05, and 448 
no pH adjustment was performed. All mobile phases were vacuum-filtered through 0.20 μm nylon 449 
membranes (Grace, Lokeren, Belgium) before use. Different mobile phases and elution programs 450 
were tested starting from 100% aqueous phase; however, in IAM-LC the latter condition did not 451 
allow the elution of the most lipophilic bases in a reasonable amount of time. Stock solutions of all 452 
drugs were prepared by dissolving 10 mg in 1 mL of methanol except for i) quinidine and 453 
theobromine, for which stock concentrations of 1 mg·mL
−1
 and 200 μg·mL−1, respectively, were 454 
used, ii) caffeine and theophylline, which were dissolved in water (10 mg·mL
−1
), iii) domperidone, 455 
which was dissolved in dimethyl sulfoxide (10 mg·mL
−1
) and iv) chlorpromazine, which was 456 
dissolved in acetonitrile. Stock solutions were stored at 4 °C, except for atenolol, zidovudine, 457 
chlorambucil and rifampicin, which were stored at −20 °C. Working solutions were freshly 458 
prepared at the beginning of each day by dilution, with the mobile phase, of the stock solutions to 459 
50 μg·mL−1 for all the analytes, except for valproic acid and halothane that were diluted to 250 460 
μg·mL−1.  461 
4.5 DATA SOURCES  462 
Log BB values were taken from the literature
18–24
. pKa values were obtained from the literature
21
 463 
except for amobarbital, donepezil, fluphenazine, hydroxyzine, ketorolac, paroxetine and ropinirole, 464 
whose values were calculated by the software Marvin Sketch 15.1 for Mac OS X
28
.    465 
4.6 SOFTWARE 466 
 467 
4.6.1 MOLECULAR MODELING  468 
Molecular modeling was performed by the software Vega ZZ 3.0.5 for Windows-based PCs
31
. The 469 
starting three-dimensional structures of the considered molecules were downloaded from PubChem 470 
database
32
 and they were considered in both zero atomic charge and ionized form. The Gasteiger – 471 
Marsili
33
 method, along with CHARMM
34,35,36 
force field,  was applied to calculate the atomic 472 
charges required to perform the next molecular mechanics calculations. An extensive 473 
conformational analysis was carried out in vacuum by using the Boltzmann Jump method 474 
(MonteCarlo procedure) implemented in AMMP software
37
 which generates 1000 geometries for 475 
each compound by randomly rotating the rotors and the obtained lowest energy conformation was 476 
further optimized by performing a PM7 semi-empirical calculation with MOPAC 2012 program
38
 477 
(keywords: PM7 PRECISE MMOK). A cluster analysis was performed to select the most populated 478 
conformation states. Physico-chemical and topological/geometrical properties (Virtual logP
39
, 479 
lipole
40
, volume, polar surface area, surface accessible to the solvent, gyration radius, ovality, mass, 480 
number of atoms, angles, dihedrals, etc) were calculated by VEGA ZZ software and, finally, all 481 
molecules were inserted into a Microsoft Access database. 482 
The QSPR models were obtained by the automatic stepwise approach implemented in “Automatic 483 
linear regression” script of VEGA ZZ software, calculating regression models, including from 1 to 484 
5 independent variables. The predictive strength of the best equation was evaluated by leave-one-485 
out (LOO) cross validation and the regression coefficients were calculated to evaluate the set in 486 
terms of standard deviation of errors, angular coefficient, intercept and r
2
 of the trend line of the 487 
chart of the predicted vs. experimental activities. Descriptors with too low regression coefficient (r
2
 488 
< 0.1) were excluded and collinear descriptors were detected by evaluating the variance inflation 489 
factor (VIF) whose threshold value was set to 5. A further validation of the model having the 490 
highest predictive strength was performed via model validator script, included in Vega. 491 
 492 
4.6.2 MOLECULAR DOCKING  493 
Molecular docking calculations were carried out using AutoDock 4.2 software
41
. The 3.4 Å 494 
resolution P-glycoprotein (P-gp) crystallographic structure (mouse P-glycoprotein 3, gene: MD1A, 495 
PDB code: 4Q9H) was downloaded from Protein Data Bank (PDB) Database. Gasteiger partial 496 
charges were calculated on ligand atoms. Polar hydrogens were added to P-gp and Gesteiger
33
 497 
partial charges were calculated using AutoDock Tools
42
. Simulation boxes were centered on the 498 
ligands in the structures of P-gp-ligand complexes (PDB codes: 4Q9I, 4Q9J, 4Q9K, 4Q9L) as 499 
reported in the literature
27
. The simulation boxes were adjusted to accommodate the ligand in each 500 
complex and the sizes were between 26x26x26 Å and 30x26x30 Å. 100 runs for each simulation 501 
were performed and the Lamarckian Genetic Algorithm (number of energy evaluation: 2.5 x 10
6
) 502 
for the docking simulations was used. The choice was based on the aspect that this protocol 503 
provides the most efficient search for general applications, and is typically effective for systems 504 
with about 10 rotatable bonds in the ligand. The acidic compounds having pKa < 7.4 and the basic 505 
ones having pKa > 7.4 were considered in their dissociated forms. Gasteiger-Marsili
33
 electric 506 
charges were supplied. Amphoteric drugs were assumed in their prevalent forms as calculated by 507 
the software MarvinSketch
28
. For the analytes supporting one or more stereocenters, the following 508 
arrangements were undertaken. When the drugs were administered as racemic mixture (Atenolol, 509 
Citalopram, Donepezil, Eserine, Halothane, Hexobarbital, Hydroxyzine, Ibuprofen, Ketorolac, 510 
Mianserin, Nicotine, Omeprazole, Oxazepam, Pindolol, Promethazine, Venlafaxine and 511 
Verapamil), each stereoisomer was docked into each site of the P-gp and the binding energies 512 
presented are the averages of those of the stereoisomers included in the mixtures. On the contrary, 513 
when the log BB values referred to a specific stereoisomer (Rifampicine, Zidovudine, 514 
Levofloxacin) as that was the one administered in the log BB determinations, only this was docked. 515 
When a new stereocenter was created because of protonation, as for instance occurs for tertiary 516 
amines supporting different groups, both configurations were tested. The consistency of the results 517 
was analyzed by clustering spatially the docked conformations. This step was necessary because of 518 
the stochastic nature of the search methods, that are used to predict optimal docked conformations. 519 
4.7 PROCESSING 520 
The chromatographic retention coefficients of each analytes were calculated by using the following 521 
expression:  522 
k = 
0
0
t
ttr 
 523 
in which tr is the retention time of the compound of interest and t0 the retention time of a non-524 
retained compound (acetone). All reported log k values are the average of at least three 525 
measurements; for each log k value the 95% confidence interval associated with each value never 526 
exceeded 0.04.  527 
Three different sets of properties were generated. At first, all the analytes were considered as 528 
uncharged (having full charge equal to 0), subsequently analytes having acidic or basic functions 529 
were considered fully ionized and zwitterions were considered with both the acidic and basic 530 
functions in their charged forms. Eventually, a weighted average of the static properties at pH 7.4 531 
according to the pKa of each analyte was performed; for zwitterions, the relative abundance of each 532 
microspecies (zero atomic charges, zwitterion, anion and cation) in solution at the physiological pH 533 
(7.4) was calculated by the software Marvin Sketch 15.1 for Mac OS X
28
. This approach was also 534 
extended to the conformational analysis performed in vacuum, yielding three different sets of 535 
conformational properties, i.e. i) conformational properties of the forms of the analytes having zero 536 
atomic charges, ii) conformational properties of the ionized forms of the analytes, and iii) average 537 
of the conformational properties at pH 7.4 according to the pKa of each analyte and the calculated 538 
microspecies distribution for zwitterions. For each of the properties taken into account (Molecular 539 
lipophilicity potential (MLP)
39
, lipole
40
, volume, polar surface area, superficial area, gyration 540 
radius, ovality, volume diameter, dipolar moment, etc), minimum and maximum value, average, 541 
range and standard deviation for each population of conformers were calculated and incorporated in 542 
the statistical models. An additional deal of molecular descriptor were calculated by the software E-543 
Dragon
30
.  544 
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LIST OF ABBREVIATIONS 548 
 549 
CNS Central Nervous System; D/Dr05 distance/detour ring index of order 5; Impropers  Number of 550 
improper angles (out of plane); HbDon Number of H-bond donor groups; HbAcc  Number of H-551 
bond acceptor groups; IAM Immobilized artificial membrane; MD Dipole Moment (Debye); MLC 552 
Micellar liquid chromatography; MLP Molecular Lipophilicity Potential; nRCOOH number of 553 
carboxylic group (aliphatic); PLS Partial Least Squares; Psa Polar Surface Area (Å
2
); P-gp P-554 
glycoprotein; SDS sodium dodecyl sulphate; TPSA (NO) topological polar surface area using N,O 555 
polar contributions; TPSA (Tot) topological polar surface area using N,O,S,P polar contributions.  556 
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